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Background: The choice of anaesthetic agent for electroconvulsive therapy (ECT) depends on seizure duration, haemodynamic 
and recovery parameters. The aim of the study was to assess the effects of dexmedetomidine premedication on haemodynamic, 
seizure duration, recovery characteristics and agitation following ECT.
Material and method: 60 patients aged 18–60  years scheduled for ECT were enrolled in the study. Dexmedetomidine (0.5   
μg/kg) diluted to 10 ml with 0.9% saline or 10 ml 0.9% saline (control) were infused intravenously over 10  min before induction of 
anaesthesia with thiopentone. Motor seizure duration, heart rate, mean arterial blood pressure, time to spontaneous respiration, 
obeying verbal commands and post-ECT agitation score were recorded. Statistical analysis was carried out using MS Excel and 
Primer of Biostatistics.
Results: Post-ECT rise in mean arterial blood pressure (MAP) and heart rate (HR) in the dexmedetomidine group was significantly 
less (p < 0.001) compared with the control group at 1, 3, and 5 mins. Motor seizure duration was comparable in both groups. Mean 
agitation score was significantly low in the dexmedetomidine group (1.5 ± 0.50) compared with the control group (1.93 ± 0.52).
Conclusion: A dexmedetomidine dose of 0.5 μg/kg IV administered over 10 min before the induction of anaesthesia may be 
useful in preventing the acute hyperdynamic responses to ECT and post-ECT agitation without altering the duration of seizure 
activity and recovery time.
Keywords: anaesthesia, dexmedetomidine, ECT
Introduction
Electroconvulsive therapy (ECT) is very effective for many 
psychiatric disorders such as severe depression, schizophrenia 
and bipolar disorder. All ECTs are performed under general 
anaesthesia with neuromuscular blockade. The goals during 
general anaesthesia for ECT are to produce an unconscious 
patient with muscle paralysis and amnesia.1 ECT is associated 
with hyperdynamic response due to increased concentrations of 
catecholamine. Increase in catecholamine leads to an acute rise 
in heart rate and blood pressure. This acute hyperdynamic 
response may lead to cardiac dysrhythmias, myocardial ischemia 
and infarction. To attenuate this acute hyperdynamic response, 
many pharmacological agents such as beta blockers, calcium 
channel blockers, alpha2-agonists, direct-acting vasodilators 
and local anaesthetics were tried.2–5
Dexmedetomidine is a potent as well as highly selective α2-
adrenergic agonist with a sedative, sympatholytic and analgesic 
effect. It has been described as a safe and effective additive in 
many anaesthetic applications and analgesic techniques.6
The physiological response resulting from the stimulation of α2-
adrenergic receptors varies and depends on their location in the 
central nervous system (CNS). Their stimulation decreases 
calcium entry in the nerve terminals resulting in an inhibitory 
effect on neurotransmitter release thus facilitating analgesia and 
attenuating stress response. Dexmedetomidine is used to 
attenuate the stress response for haemodynamic stability and to 
reduce the dose of anaesthetic agent.7,8 For ECT, the optimal 
seizure duration remains unclear. An adequate seizure in ECT is 
defined as one that lasts longer than 30 sec. Too short (< 10 sec) 
or too long (>120 sec) may reduce clinical efficacy.9,10 Emergence 
agitation (excitement, restlessness and panic) may occur in some 
patients after ECT.10 Dexmedetomidine is effective in the 
management of emergence agitation following ECT.5 The aim of 
our work is to study the efficacy of dexmedetomidine used in 
premedication for attenuating hyperdynamic response to ECT 
and along with this its effect on seizure duration, recovery 
characteristics and agitation following ECT.
Material and methods
After institutional ethics committee approval, 65 patients scheduled 
for ECT were evaluated using inclusion and exclusion criteria, and 
60 patients were enrolled in this prospective randomised double 
blind controlled study (Figure 1). The patients were informed about 
the procedure and the study. Informed consent was obtained from 
the patients and caretakers in the prescribed form. The study was 
conducted in accordance with the Declaration of Helsinki and 
Good Clinical Practice. Inclusion criteria were as follows: patients 
scheduled for ECT, physical status ASA I and II, age between 18 and 
60 years, without a history of cardiovascular disease, no history of 
using beta-receptor blocker drugs or narcotic usage and should not 
be sensitive to dexmedetomidine.
The exclusion criteria included serious physical disease, baseline 
bradycardia (HR < 50 beats/min) such as cardiovascular disease, 
cerebrovascular disorder, intracranial hypertension, respiratory 
tract disease, previous fracture, glaucoma, arterial aneurysm, 
history of seizures, ASA III–V physical status, history of allergy to 
the study drugs and pregnancy.
Chronic antidepressant medications were continued. The patient 
was kept nil by mouth for at least 8 h and patients were 
encouraged to empty their bladder before ECT.
The page number in the footer is not for bibliographic referencingwww.tandfonline.com/ojaa 24
Southern African Journal of Anaesthesia and Analgesia 2016; 22(6)181 Southern African J rnal of Anaesthesia and Analgesia 2016; 22(6):180–184
After premedication with ondansetron 4 mg and glycopyrrolate 
0.2  mg intravenously, 0.5  μg/kg dexmedetomidine (diluted to 
10 ml with 0.9% saline) for the dexmedetomidine group (Group D) 
or 10  ml 0.9% saline for the control group (Group N) was given 
intravenously over 10 min before induction of anaesthesia by an 
anaesthesiologist not involved in the recording of data. The 
patient was pre-oxygenated with 100% oxygen. All patients were 
induced with thiopentone 3 mg/kg. Induction was confirmed by 
loss of eyelash reflex. Succinylcholine in a dose of 0.5 mg/kg was 
administered after induction of anaesthesia and manual 
ventilation was done with a face mask using 100% oxygen at a 
flow rate of 8 L/min. A bite block was used to protect the patient’s 
teeth, lips and tongue. ECT was given using a constant-current 
ECT device with a current of 120 mC and frequency of 70 HZ and 
duration 0.1 s. A stimulus was given via bifrontotemporal 
electrodes and ventilation was assisted with oxygen during and 
Figure 1: Consort 2010 flow diagram.
Figure 2: Post-ECT changes in heart rate and mean arterial blood pressure.
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after the procedure. Mean arterial blood pressure (MAP), heart rate 
(HR) and oxygen saturation was recorded at baseline, 1, 3, 5, 10, 20, 
30 and 60  min after ECT. Peak heart rate after ECT was also noted.
The duration of the motor seizure was defined as the time from 
the beginning of ECT to cessation of tonic–clonic motor activity in 
the ‘isolated’ arm. The time from the end of succinylcholine 
administration until spontaneous breathing and obeying verbal 
commands was also recorded. Agitation score was evaluated after 
30 min post-ECT in the post anaesthetic care unit (PACU). The 
agitation was evaluated using an emergence agitation score in 
which 1 = sleeping, 2 = awake and calm, 3 = irritable and crying, 
4 = inconsolable crying, 5 = severe restlessness and disorientation.5
Probable side effects including nausea, vomiting, bradycardia, 
tachycardia, hypotension/hypertension, respiratory depression 
and hypoxemia were recorded after the electrical stimulus until 
the patient was discharged from the post-anaesthetic care unit 
(PACU) to the psychiatry ward. Standard monitoring was applied 
during recovery and the patient observed for 2 h in PACU before 
being moved to the ward. Respiratory depression was defined as 
respiratory rate less than 10 breaths/min, hypoxaemia was 
defined as oxygen saturation (SpO2) of 90% or less, bradycardia 
was defined as HR less than 50 beats/min, tachycardia as HR 
more than 120 beats/min, hypotension defined as MAP less than 
60 mmHg, and hypertension as MAP more than 120 mmHg.
The primary outcome of the study was the efficacy of 
dexmedetomidine to attenuate post-ECT hyperdynamic response 
and a secondary outcome was studied in terms of its effect on 
motor seizure duration, recovery parameters and post-ECT agitation.
Sample size calculation was done by using Winpepi software in 
which we referred to the mean and standard deviation of a 
previous study by Shams and El-Masry.5 We took a level of 
significance of 5% and power of study of 80%. From these 
calculations the exact sample size calculated was 23 for each 
group. Catering for willingness of the patient, inclusion–
exclusion criteria and loss to follow-up, we took a sample size of 
30 in each group.
Data were expressed as mean ± standard deviation. Quantitative 
variables are presented as mean ± SD and a t-test was used to 
compare significance between the two groups. Qualitative data 
were expressed as number (%) and analysed using a chi-square 
test. A p-value of  <  0.05 was taken as significant. Data were 
analysed using Microsoft Excel® (Microsoft Corp, Redmond, WA, 
USA) and the software Primer of Biostatistics 6.0.
Results
Demographic variables were comparable in both the groups 
(Table 1).
Motor seizure duration, time to spontaneous breathing and time 
to respond to verbal commands were comparable in both groups 
while mean agitation score and peak heart rate were significantly 
high in Group N (Table 2).
An agitation score of 3 was observed in 3 (10%) patients in group 
N while none of patient in group D had an agitation score of 3. 
Significantly more patients in Group D had an agitation score of 
1 as compared with Group N (Table 3).
No significant side effects were observed in either group 
(Table 4).
Rise in heart rate and mean arterial blood pressure was 
significantly less in Group D as compared with Group N (Figure 2).
Table 1: Demographic data
Variable Group N Group D p-value Significance
Age (yrs) 37.47 ± 8.54 35.7 ± 7.97 0.410 Not significant
Gender (M/F) 16/14 13/17 0.440 Not significant
Body weight 
(kg) 61.67 ± 8.18 60.23 ± 5.57 0.430 Not significant
Table 2: Motor seizure duration and recovery characteristics
Variable Group N Group D p-value Significance
Motor seizure 




121.83 ± 49 125 ± 47.54 0.750 Not significant
Time to  respond 
to  verbal com-
mands (sec)
329.67 ± 47.38 343.33 ± 33.56 0.389 Not significant
Mean agitation 
score 1.93 ± 0.52 1.5 ± 0.50 0.0018 Significant
Peak heart rate 124.1 ± 20.54 97.46 ± 9.5 0.000 Highly  significant
Table 3: Agitation score
Agitation score Group N (n = 30) Group D (n = 30) p-value
1 5 (16.7%) 15 (50%) 0.014
2 22 (73.3%) 15 (50%) 0.111
3 3 (10%) 0 0.236
4 0                    0 –
Table 4: Side effects
Side effect Group N (n = 30) Group D (n = 30)
Nausea/vomiting 1 (3.3%) –
Bradycardia – 1 (3.3%)
Hypotension – –
Respiratory depression – –
Hypoxemia                      – –
Table 5: Post-ECT changes in heart rate in group N and group D
Heart rate (beats/
min)
Group N Group D p-value
Baseline 81.73 +/− 11.8 77.86 +/− 12 0.231
1 min 119.26 +/− 14 92.03 +/− 13.5 < 0.001
3 min 114.03 +/− 12.29 88.87 +/− 12.8 < 0.001
5 min 98.9 +/− 9.65 83.86 +/− 10.58 < 0.001
10 min 78.99 +/− 10 76.86 +/− 9.3 0.396
20 min 77.12 +/− 7.81 76.21 +/− 10.1 0.912
30 min 76.56 +/− 8.17 75.57 +/− 7.91 0.635
60 min 76 +/− 7.71 75.67 +/− 8.3 0.874
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without serious side effects. In our study post-ECT hyperdynamic 
response was significantly less in the dexmedetomidine group. 
Heart rate and mean arterial blood pressure were significantly 
less at 1, 3 and 5 min in group D compared with group N. This 
observation was similar to the findings of Begec et al.8 Begec et 
al. found that heart rate and MAP values were lower in a 
dexmedetomidine group at 0, 1, 3 and 10  min. Shams and El-
Masry also had similar results as MAP and heart rate were on the 
lower side in a dexmedetomidine group as compared with a 
control group, in this study a combination of ketamine and 
propofol was used for induction.5
Dexmedetomidine is emerging in the literature as an agent to 
manage severe post-ECT agitation due to its sedative and 
anxiolytic properties. In our study, the agitation score was also 
significantly less in the dexmedetomidine group (1.5 ± 0.50 sec) 
compared with the control group (1.93  ±  0.52 sec). This 
observation was similar to those of Shams and El-Masry, Mizrak 
et al. and Cohen and Stewart.5,7,11 Shams and El-Masry found that 
the number of patients with an agitation score of  >  2 was 
significantly lower in the dexmedetomidine group (1.4%) 
compared with the control group (8.6%). Fiftteen (50%) patients 
in the dexmedetomidine group were comfortably sleeping (no 
hypoxaemia or respiratory depression) at the end of half an hour 
as compared with 5 (16.6%) patients in the control group. Three 
(10%) patients in the control group had an agitation score of 3 as 
compared with the dexmedetomidine group in which no patient 
had an agitation score of 3.
Motor seizure duration, time to spontaneous breathing and 
obeying commands were comparable between both groups. No 
significant side effects were observed in either group.21 These 
findings were similar to those of Shams and El-Masry, Mizrak et 
al., Begec et al. and Cohen and Stewart.5,7,8,11
Conclusion
Dexmedetomidine is effective in attenuating acute hyperdynamic 
response to ECT without altering seizure duration and recovery 
from anaesthesia, with the added benefit of decreasing post-ECT 
agitation.
Limitations of study
This was a controlled study and we did not compare its effect 
with other agents such as short-acting opioids or beta blockers 
used for attenuating a hyperdynamic response. EEG seizure 
duration was not recorded, but only that of motor seizure 
duration. Seizure duration can be recorded more accurately with 
EEG. Patient satisfaction was not recorded. The difference in 
requirement of thiopentone for induction in each group was not 
studied.
Acknowledgement – The authors would like to acknowledge the 
Department of Psychiatry for their kind cooperation during this 
study.
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Post-ECT heart rate and mean arterial blood pressure were 
significantly higher in the control group compared with the 
dexmedetomidine group at 1, 3 and 5 min (Tables 5 and 6). Peak 
HR was lower in the dexmedetomidine group compared with the 
control group (p < 0.001 [highly significant]). Motor seizure 
duration in the control group (22.9 ± 6.47 seconds) was similar to 
that in the dexmedetomidine group (25  ±  70.205  seconds) 
(p > 0.05). Time to spontaneous breathing and obeying commands 
was not different between the two groups. The agitation score 
was significantly less in the dexmedetomidine group.
Discussion
ECT induces generalised tonic–clonic epileptic seizure. An electric 
current is applied transcutaneously to the brain via two electrodes 
positioned either bilaterally or unilaterally. A variety of adverse 
physiological and physical effects occur.2 Cardiovascular and 
central nervous system responses are potentially most dangerous. 
In the central nervous system, there is an increase in intracranial 
pressure, cerebral blood flow, blood–brain permeability, cerebral 
oxygen consumption and glucose utilisation. Headache, 
confusion and transient memory loss were also observed after 
ECT. In the cardiovascular system (CVS), the initial brief 
parasympathetic response lasts 10–15 sec causing bradycardia, 
hypotension or even asystole. This initial response is followed by 
a sustained sympathetic response peaking at 3–5 min associated 
with the release of catecholamine, rise in systolic blood pressure 
(30–40%) and rise in heart rate (> 20%). All this predisposes to 
cardiac dysrhythmias, myocardial ischaemia and infarction. Even 
in a normal heart, ventricular dysfunction has been noted up to 6 
h after ECT.12–18 Rapid short-acting opioid analgesics and beta 
blockers also possess a sympatholytic effect and have recently 
been investigated as adjuvants during ECT18,19 but many of them 
have been found to reduce seizure duration. The purpose of our 
study was to blunt the haemodynamic insult associated with ECT 
using dexmedetomidine.
Anaesthetic agents for ECT include thiopentone, propofol, 
ketamine, methohexitone, remifentanil, etomidate and 
sevoflurane.2–5 The choice of anaesthetic agent may influence 
seizure quality and duration, haemodynamic and recovery 
parameters. For induction of anaesthesia, we used thiopentone 
as it has minimum effect on haemodynamic and seizure 
duration.20
Dexmedetomidine exhibits sedative and anxiolytic properties 
via activation of the adrenergic receptor in the locus coeruleus 
causing inhibition of adenylyl cyclase. This results in stimulation 
of parasympathetic outflow and inhibition of sympathetic 
outflow overall causing reduction in CVS and CNS excitation. 
Dexmedetomidine has been reported to be effective in ECT 
Table 6: Post-ECT changes in mean arterial blood pressure in Group N 
and Group D
MAP (mmHg) Group N Group D p-value
Baseline 85.36 +/− 9.34 81.93 +/− 7.8 0.128
1 min 123.96 +/− 15.94 94.6 +/− 12.2 < 0.001
3 min 114.33 +/− 13.8 88.3 +/− 11.02 < 0.001
5 min 99.03 +/− 9.10 82.03 +/− 10.06 < 0.001
10 min 82.03 +/− 10.73 77.16 +/− 8.97 0.061
20 min 81.66 +/− 9.97 78.13 +/− 9.97 0.176
30 min 80.87 +/− 10.73 77.56 +/− 12.7 0.201
60 min 81.31 +/− 9.76 77.71 +/− 11.7 0.281
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